Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
NCT ID: NCT01561456
Last Updated: 2013-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2011-12-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
AXL1717 is a small molecule experimental product developed by Axelar AB as anticancer agent for oral administration. AXL1717 inhibits the insulin-like growth factor 1 (IGF-1), which is often over expressed in lung tumors and can mediate the proliferation of lung cancer cells and resistance to therapy. Results of previous preclinical and clinical studies indicate that AXL1717 will be tolerable and effective in patients with previously-treated, advanced squamous cell carcinoma (SCC) and adenocarcinoma (AC) histological subtypes of NSCLC.
This is an open label, randomized, multi-center, Phase II study to investigate AXL1717 compared to docetaxel in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the lung. Patients with previously treated, locally advanced or metastatic SCC or AC subtypes of NSCLC in need of additional treatment will be enrolled in the study. Patients will be randomized to either AXL1717 or to docetaxel group as monotherapy, in a 3:2 ratio for each NSCLC subtype. Patients in AXL1717 group will receive 400 mg AXL1717 twice daily (BID) as oral suspension for 21 days per cycle; i.e. daily for up to four cycles unless a dose interruption, delay, or reduction is required. Docetaxel will be administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study. The primary objective of the study is to compare the rate of progression-free survival (PFS) at 12 weeks between patients treated with AXL1717 and patients treated with docetaxel. Additional efficacy and safety parameters will be monitored throughout the study. Patients treated with AXL1717 who are responding to treatment or remain stable at the end of 4 cycles may be offered an extension of treatment with AXL1717.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AXL1717
AXL1717
AXL1717
AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Docetaxel
Docetaxel
Docetaxel
Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AXL1717
AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Docetaxel
Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
* Histologically confirmed diagnosis of locally advanced, or metastatic squamous cell carcinoma or adenocarcinoma histological subtypes of non-small-cell lung cancer (stage IIIB or IV)
* For patients with squamous cell histology: previously treated with first-line chemotherapy and has had disease progression during or after first-line therapy.
* For patients with adenocarcinoma histology: previously treated with one or two lines of chemotherapy.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Life expectancy ≥ 3 months
* Measurable disease by RECIST 1.1 criteria
* Hematology values: blood leukocyte count ≥ 3.0 x 109/L, blood absolute neutrophil count ≥ 1.5 x 109/L, blood platelet count ≥ 100 x109/L, hemoglobin ≥ 100 g/L (transfusions are allowed)
* Clinical chemistry values: plasma total bilirubin level ≤ upper limit of the "normal" range (ULN; i.e. reference), plasma AST or ALT ≤ 1.5 x ULN (≤ 5 times if liver metastases have been documented) and plasma creatinine ≤ 2.0 x ULN
* 12-lead ECG with normal tracings
Exclusion Criteria
* Ongoing infection or other major recent or ongoing disease that, according to the Investigator, poses an unacceptable risk to the patient
* Known primary or secondary central nervous system malignancy.
* Active or previously treated carcinomatous meningitis
* Truly non-measurable disease by RECIST 1.1 criteria, such as patients with one or more of the following without any RECIST measurable disease:
* Bone lesions
* Ascites
* Pleural or pericardial effusion
* Lymphangitis cutis or pulmonis
* Cystic lesions
* Grade 3 or higher constipation within the past 28 days or grade 2 constipation within the past 14 days before randomization.
* Active hepatitis B, active hepatitis C, or known HIV infection
* Coexisting uncontrolled medical condition, including active cardiac disease (such as unstable angina, myocardial infarction within 6 months, or New York Heart Association Class III/IV congestive heart failure), and significant dementia
* Hepatic impairment as indicated by abnormalities of transaminases (AST and/or ALT \> 1.5 × ULN or AST and/or ALT \> 5 times ULN if liver metastases have been documented) and/or increased alkaline phosphatase (\> 2.5 × ULN) considered as a result of hepatic impairment (and not from bone disease)
* History of cancer that has required treatment or been active within the past 5 years, other than NSCLC, basal cell carcinoma, or cervical carcinoma in situ
* Major surgical procedure within 4 weeks prior to randomization
* More than one prior anti-tumor systemic therapy for advanced squamous cell NSCLC, and more than two prior lines of chemotherapy for advanced adenocarcinoma NSCLC
* Previous use of docetaxel in any line of therapy
* Women of child bearing potential (WOCBP) who do not consent to using acceptable methods of contraception
* Women who are breast-feeding or have a positive pregnancy test at screening
* Current participation in any other investigational clinical trial or any administration of an investigational agent within 4 weeks of study drug administration
* ECOG performance status \> 2
* Life expectancy \< 3 months
* Known or suspected hypersensitivity to AXL1717 or docetaxel or to drugs formulated with polysorbate 80
* Lack of suitability for participation in the trial, for any reason, as judged by the Investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axelar AB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Bergqvist, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Uppsala University Hospital, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
State Medical Institution: Republic Scientific Oncology Center
Poselok, Minsk Oblast, Belarus
Gomel Regional Clinical Oncology Center
Homyel, , Belarus
Minsk City Clinical Oncology Center
Minsk, , Belarus
Vitebsk Regional Clinical Oncology Center
Vitebsk, , Belarus
Semmelweis University; Clinic for Pulmonology
Budapest, , Hungary
University of Debrecen Medical and Health Science Center, Clinic of Pulmonology
Debrecen, , Hungary
Kenezy Gyula County Hospital
Debrecen, , Hungary
Hospital for Thoracic Diseases of Csongrad County Local Government
Deszk, , Hungary
Wladyslaw Bieganski Regional Specialist Hospital
Grudziądz, , Poland
Maria Sklodowska-Curie Institute of Oncology in Warsaw
Warsaw, , Poland
State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncology Center
Chelyabinsk, , Russia
City Clinical Hospital #1
Novosibirsk, , Russia
Orel Oncology Center
Oryol, , Russia
St. Petersburg State Medical Institution Municipal Clinical Oncology Center
Saint Petersburg, , Russia
State Higher Educational Institution St. Petersburg State Medical University n. a. after I. P. Pavlov under Federal Agency for Healthcare and Social Development, Research Institute of Pulmonology
Saint Petersburg, , Russia
Tula Regional Oncology Center
Tula, , Russia
Sverdlovsk Regional Oncology Center
Yekaterinburg, , Russia
Dnipropetrovsk City Multispecialty Clinical Hospital #4
Dniepropetrovsk, , Ukraine
Public Clinical Treatment and Prophylaxis Institution: Donetsk Regional Antitumor Center
Donetsk, , Ukraine
Kharkiv, State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences
Kharkiv, , Ukraine
Public Healthcare Institution: Kharkiv Regional Clinical Oncology Center
Kharkiv, , Ukraine
Kyiv City Oncology Hospital
Kyiv, , Ukraine
Lviv State Regional Treatment and Diagnostics Oncology Center
Lviv, , Ukraine
Zakarpattia Regional Clinical Oncology Center
Uzhhorod, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002007-15
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AXL-003
Identifier Type: -
Identifier Source: org_study_id